Digest Réseau Comment ça marche
Réseau
/
Sociétés
No
Non vérifié

Novo Nordisk A/S

Ce que nous écrivons

FinanceIndustrie pharmaceutiqueManagement/Organisation d'EntreprisePolitique ÉtrangèrePublicité/Marketing/Médias/Communication

101 communiqués de presse

Voir tous les communiqués de presse
11/06/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo Nordisk A/S: IT Security incident at Novo Nordisk
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
11/06/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
02/06/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
26/05/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
22/05/2026
Industrie pharmaceutique
Politique Étrangère
Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
22/05/2026
Industrie pharmaceutique
Annonces Économiques
Politique Étrangère
Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
19/05/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
12/05/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
12/05/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
11/05/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0